Table 3 Univariate and multivariate analyses of PFS in patients

Age (years)

≤60/> 60

1.178

0.674–2.058

0.566

NI

0.956

0.547–1.671

0.874

NI

Gender

Female / Male

1.587

0.905–2.783

0.107

NI

2.284

1.269–4.112

0.006

1.798

0.966–3.330

0.064

Tumor size (cm)

≤2/2~4/>4

0.787

0.490–1.265

0.324

NI

0.970

0.596–1.579

0.903

NI

Tumor grade

Well / Moderate / Poor

1.135

0.735–1.753

0.568

NI

1.333

0.855–2.079

0.205

NI

LN metastasis

Absent / Present

0.900

0.501–1.614

0.723

NI

1.078

0.600–1.938

0.801

NI

Tumor site

Head / Body / Tail

0.935

0.621–1.407

0.748

NI

0.995

0.650–1.525

0.983

NI

WBC (*10⁹)

≤10/>10

1.149

0.486–2.718

0.751

NI

1.019

0.431–2.411

0.965

NI

HGB (g/L)

≤120/>120

0.685

0.308–1.527

0.355

NI

0.477

0.211–1.076

0.075

NI

PLT (*10⁹)

≤300/>300

0.613

0.261–1.438

0.261

NI

0.676

0.287–1.592

0.370

NI

ALT (U/L)

≤40/>40

0.729

0.373–1.426

0.356

NI

0.737

0.375–1.447

0.375

NI

AST (U/L)

≤40/>40

0.662

0.309–1.417

0.288

NI

0.691

0.320–1.490

0.345

NI

ALP (U/L)

≤100/>100

0.823

0.459–1.476

0.514

NI

0.790

0.439–1.423

0.433

NI

GGT (U/L)

≤45/>45

0.693

0.390–1.230

0.210

NI

0.741

0.414–1.327

0.313

NI

ALB (g/L)

≤40/>40

0.602

0.253–1.429

0.250

NI

0.666

0.281–1.582

0.357

NI

TBIL (umol/L)

≤20.5/>20.5

0.691

0.336–1.423

0.316

NI

0.721

0.350–1.487

0.376

NI

IBIL (umol/L)

≤15/>15

0.884

0.317–2.461

0.813

NI

0.769

0.276–2.144

0.616

NI

CRP (ng/L)

≤3/>3

1.840

1.030–3.286

0.040

1.586

0.877–2.866

0.127

1.763

0.970–3.202

0.063

NI

CEA (ng/mL)

≤5/>5

1.466

0.835–2.572

0.183

NI

1.464

0.829–2.586

0.189

NI

CA19–9 (U/ml)

≤35/>35

2.078

1.009–4.279

0.047

1.908

0.917–3.968

0.084

2.530

1.179–5.429

0.017

2.032

0.904–4.569

0.086

Chemotherapy

With IRE/ With radiotherapy

0.557

0.310–1.000

0.050

0.582

0.322–0.950

0.048

0.435

0.242–0.783

0.005

0.438

0.243–0.790

0.006

Cheotherapy type

FOLFIRINOX/Gem

0.965

0.733–1.271

0.803

NI

1.014

0.768–1.340

0.921

NI